In short
This article discusses a clinical trial investigating the long-term safety and effectiveness of a gene therapy treatment for Leukocyte Adhesion Deficiency-I (LAD-I). The study focuses on a drug called RP-L201, which uses genetically modified stem cells to treat this rare genetic disorder. Patients who previously participated in an earlier phase of the trial are being followed for up to 15 years to monitor the treatment's long-term effects and potential benefits.
At a glance
- Study Type
- Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
- Treatment
- RP-L201 (autologous CD34+ hematopoietic stem cells genetically modified with lentiviral vector encoding the CD18 gene)
- Duration
- Up to 15 years post-infusion
- Visit Schedule
- Every 6 months up to Year 5, then yearly until Year 15
- Primary Objectives
- Evaluate long-term safety and efficacy of RP-L201
- Key Endpoints
- Infection rates, skin/oral lesions, adverse events, malignancy, graft failure, GvHD, survival rates, CD18 expression
- Eligibility
- Participants from previous Phase I/II study who received RP-L201
What is Leukocyte Adhesion Deficiency-I (LAD-I)?
Leukocyte Adhesion Deficiency-I (LAD-I) is a rare genetic disorder that affects the immune system. In this condition, white blood cells (leukocytes) are unable to move properly to sites of infection in the body. This leads to recurrent and severe infections, as well as other health problems.
What is RP-L201?
RP-L201, also known as LADICell, is an innovative gene therapy product designed to treat LAD-I. It is classified as an advanced therapy medicinal product, specifically a gene therapy. RP-L201 is currently being studied in clinical trials to evaluate its safety and effectiveness in treating patients with LAD-I.
How Does RP-L201 Work?
RP-L201 works by using the patient's own cells to correct the genetic defect causing LAD-I. Here's a simplified explanation of the process:
- Cell collection: Doctors collect special blood-forming stem cells (called CD34+ hematopoietic stem cells) from the patient's blood.
- Genetic modification: These cells are then modified in a laboratory using a lentiviral vector. This vector is a harmless virus that carries a correct copy of the ITGB2 gene, which is faulty in LAD-I patients.
- Cell infusion: The modified cells are then given back to the patient through an intravenous infusion.
- Cell regeneration: These modified cells can then produce new blood cells that have the correct gene, potentially correcting the LAD-I defect.
The ITGB2 gene provides instructions for making a protein called CD18, which is crucial for proper immune function. By introducing a correct copy of this gene, RP-L201 aims to restore normal immune function in patients with LAD-I.
The Clinical Trial for RP-L201
A clinical trial is currently underway to evaluate the long-term safety and effectiveness of RP-L201 in patients with LAD-I. This trial, known as a Long-Term Follow-Up (LTFU) study, is designed to monitor patients who have received RP-L201 treatment for up to 15 years after their initial treatment.
Who is Eligible for the Treatment?
The current long-term follow-up study is specifically for patients who have already received RP-L201 in a previous clinical trial. To be eligible, patients must:
- Have been enrolled in the Phase I/II parent study RP-L201-0318
- Have received RP-L201 in that study
- Be willing and able to follow the study visit schedule and other requirements
- Provide informed consent to participate in the study
Safety and Efficacy Monitoring
The long-term follow-up study is designed to carefully monitor the safety and effectiveness of RP-L201 over time. Some key aspects being monitored include:
- Infections: Any significant infections that require hospitalization or intravenous antibiotics
- LAD-I symptoms: Any new skin or oral lesions that might be caused by LAD-I
- Side effects: Any late-occurring serious side effects that might be related to the treatment
- Cancer risk: Any occurrence of cancer that might be related to the treatment
- Treatment effectiveness: Whether the treatment continues to work over time
- Graft-versus-host disease (GvHD): Any signs of this condition, which can occur after some types of cell therapies
Potential Benefits of RP-L201
While the long-term effects are still being studied, the potential benefits of RP-L201 for LAD-I patients may include:
- Reduction in the number and severity of infections
- Fewer and shorter hospital stays due to infections
- Improvement or resolution of LAD-I-related symptoms, such as skin rashes or gum problems
- Normalization of white blood cell counts
- Long-term presence of the corrected gene in the patient's blood cells
- Improved overall survival and quality of life
It's important to note that RP-L201 is still an experimental treatment, and more research is needed to fully understand its long-term effects and benefits. Patients considering this treatment should discuss it thoroughly with their healthcare providers to understand the potential risks and benefits.